Multiple preclinical studies have shown that specific small-molecule ALK TKIs can delay tumor growth and/or induce tumor regression in xenograft and transgenic models.[10] However, few reports are available on the efficacy of ensartinib treatment for metastasis IMT, with no consistent prediction of the efficacy of TKI in metastatic IMT. This evidence concerns the gene ALK and neoplasm.